Ipsen to Present New Data on Enhancement of Patient Care at the 16th European Neuroendocrine Tumor Society (ENETS) Annual Conference
Ipsen (Euronext: IPN; ADR: IPSEY) today announced that they are looking forward to revealing 17 presentations that detail their research into neuroendocrine tumors (NETs) at the 16th European Neuroendocrine Tumor Society (ENETS) Annual Conference, which is taking place in Barcelona, Spain between 6th-8th March 2019.
One of the key presentations, titled (Abstract #H14) ‘Development of a new and improved delivery system for lanreotide autogel/depot to further enhance care for patients with NETs and acromegaly’, reports results from five separate, but complementary studies designed to inform and test enhancements to the existing Somatuline® Autogel® (lanreotide) pre-filled syringe.1
Input from patients and their caregivers, as well as nurses and other healthcare professionals, was used to design a new pre-filled syringe1 that was submitted to the European Union as a type II variation via a work-sharing procedure with HPRA (Ireland) as the reference country. Following a positive outcome of the work-sharing procedure, each member state would consider a national approval. Notable new features are modified ergonomics and handling, a needle shield removal system, an injection process with plunger support and heightened ease of use.1
“It is our mission to ensure patients continue to receive optimized care as they navigate the challenges of living with NETs and acromegaly,” said Sotirios Stergiopoulos, Chief Medical Officer at Ipsen. “The data we are sharing at this year’s ENETS conference underscores our commitment to understanding the patient experience and to supporting a multidisciplinary treatment approach to make treatment administration as simple as possible whether in hospital or at home.”
“For nurses and other healthcare practitioners treating patients with NETs or acromegaly, the value of innovation across the entire treatment landscape supports our ability to provide the best care for our patients,” said Daphne T Adelman, Clinical Nurse Specialist from Northwestern University in Chicago, U.S. and one of the authors of the study. “As a nurse who administers treatments to patients often, efficient pre-filled syringes allow me to save time and focus on patients and their needs.”
Also, being highlighted are results from:
(Abstract #H18) Tumour growth rate (TGR) to monitor growth/predict response to lanreotide autogel (LAN) use before, during and after peptide receptor radionuclide therapy (PRRT) in advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs): data from PRELUDE
This abstract has been selected for a poster walk during ENETS’ scientific program and will report effectiveness data and post-hoc analyses of tumor growth rate (TGR) as a measure of response to LAN–PRRT (lanreotide autogel – peptide receptor radionuclide therapy).
(Abstract #M03) ATLANT, phase 2 study combination trial between long acting somatostatin analogue (SSA) lanreotide (LAN) and temozolomide (TMZ) in progressive thoracic (lung / thymus) well differentiated NET (carcinoid) (TNETS).
(Abstract #F22) Exploratory assessment of the clinical value of baseline (BL) circulating tumour cells (CTC) to predict symptomatic response in pts with functioning midgut neuroendocrine tumours (NETs) receiving lanreotide autogel (LAN): CALM-NET study results
In addition to these posters, Ipsen will share data from the following 13 company sponsored or supported studies and literature reviews:
(Abstract #H17) Safety and Efficacy of 14-Day Dosing Interval of Lanreotide Autogel/Depot (LAN) For Patients With Pancreatic or Midgut Neuroendocrine Tumours (NETs) Progressing on LAN Every 28 Days: The Prospective, Open-label, International, Phase 2 CLARINET FORTE Study
(Abstract #P04) Lanreotide autogel 120mg (LAN) in patients (pts) with locally advanced or metastatic gastroenteropancreatic neuroendocrine tumours (GEP-NETs): prospective observational NETways study
(Abstract #D13) Satisfaction Survey of Administration Modes for Long-Acting (LA) Somatostatin Analog (SSA) Therapy in Patients (pts) with Neuroendocrine Tumuors (NETs): Results of Cognitive Interviews With Patients and Nurses
(Abstract #J15) The Effect of Carcinoid Syndrome Diarrhea (CSD) Interventions on Patient Experience Outcomes: a Systematic Literature Review (SLR)
(Abstract #J08) Differential Diagnosis (DDx) of Carcinoid Syndrome Diarrhea (CSD): a Systematic Literature Review (SLR)
(Abstract #H25) Evaluation of the use of resources and costs associated with Uncontrolled or Controlled Carcinoid Syndrome (CS) in patients (pts) with Neuroendocrine Tumours (NETs) in Spain: RECOSY study
(Abstract #F10) Relationship between biomarkers and number of liver metastases at the time of diagnosis of small intestinal neuroendocrine tumors
(Abstract #A11) Evaluation of gene expression changes associated with response to somatostatin analogues (SSAs) in gastrointestinal (GI) neuroendocrine tumors (NETs)
(Abstract #J07) Long-term Treatment with Telotristat Ethyl (TE) in Patients with Carcinoid Syndrome (CS) Symptoms: Results from TELEPATH Study
(Abstract #P05) TELEFIRST: A randomized phase III clinical trial of Lanreotide (LAN) combined with Telotristat ethyl (TE) or placebo (PBO) for the First-line treatment in patients (pts) with advanced well-differentiated (wd) small intestinal neuroendocrine tumours (siNET) with highly-functioning carcinoid syndrome (CS)
(Abstract #K30) OPS-C-001: A Phase I/II Study To Investigate Safety, Tolerability, Biodistribution, Dosimetry and Preliminary Efficacy of 177Lu-OPS201 for the Therapy of Somatostatin Receptor (SSTR)-Positive Neuroendocrine Tumours (NETs)
(Abstract #P08) Study to evaluate the optimal dose of 68Ga-OPS202 as a PET imaging agent in patients with GEP-NETs
(Abstract #D33) Establishment of a NET data base in a German tertiary referral center; preliminary results
About SOMATULINE ®2
Somatuline® Autogel® is made of the active substance lanreotide, which is a long-acting somatostatin analogue that inhibits the secretion of growth hormone and certain hormones secreted by the digestive system. The main indications of Somatuline® and Somatuline® Autogel® are:2
- The treatment of individuals with acromegaly when the circulating levels of Growth Hormone (GH) and/or Insulin-like Growth Factor-1 (IGF-1) remain abnormal after surgery and/or radiotherapy, or in patients who otherwise require medical treatment.
- The treatment of grade 1 and a subset of grade 2 (Ki-67 index up to 10%) gastroenteropancreatic neuroendocrine tumors (GEP-NETs) of midgut, pancreatic or unknown origin where hindgut sites of origin have been excluded, in adult patients with unresectable locally advanced or metastatic disease.
- The treatment of symptoms associated with neuroendocrine (particularly carcinoid) tumors.
Important Safety Information
- The detailed recommendations for the use of Somatuline Autogel are described in the Summary of Product Characteristics (SmPC), available here.
About XERMELO ®3
Xermelo® is a novel, orally administered, inhibitor of the enzyme tryptophan hydroxylase (TPH). Through inhibition of TPH, the rate-limiting step in the synthesis of serotonin, Xermelo® was designed to reduce the production of serotonin within neuroendocrine tumors.
Xermelo® (telotristat ethyl) is commercialized by Ipsen in all territories excluding the United States and Japan, where Lexicon retains the rights. Lexicon has approval for Xermelo® in the U.S. as a first and only orally administered therapy for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy.
Xermelo® is approved in Europe for the treatment of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analogue therapy.
Important Safety Information
- The detailed recommendations for the use of Xermelo are described in the Summary of Product Characteristics (SmPC), available here.
1 Data on File. ENETS ‘19
2 Somatuline Autogel SmPC. November 2018
3 Xermelo SmPC. January 2019
Ipsen is a global specialty-driven biopharmaceutical group focused on innovation and Specialty Care. The group develops and commercializes innovative medicines in three key therapeutic areas - Oncology, Neuroscience and Rare Diseases. Its commitment to Oncology is exemplified through its growing portfolio of key therapies for prostate cancer, neuroendocrine tumors, renal cell carcinoma and pancreatic cancer. Ipsen also has a well-established Consumer Healthcare business. With total sales over €2.2billion in 2018, Ipsen sells more than 20 drugs in over 115 countries, with a direct commercial presence in more than 30 countries. Ipsen's R&D is focused on its innovative and differentiated technological platforms located in the heart of the leading biotechnological and life sciences hubs (Paris-Saclay, France; Oxford, UK; Cambridge, US). The Group has about 5,700 employees worldwide. Ipsen is listed in Paris (Euronext: IPN) and in the United States through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information on Ipsen, visit www.ipsen.com.
Forward Looking Statement
The forward-looking statements, objectives and targets contained herein are based on the Group’s management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect the Group’s future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words "believes", "anticipates" and "expects" and similar expressions are intended to identify forward-looking statements, including the Group’s expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by the Group. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising product in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. The Group must face or might face competition from generic products that might translate into a loss of market share. Furthermore, the Research and Development process involves several stages each of which involves the substantial risk that the Group may fail to achieve its objectives and be forced to abandon its efforts with regards to a product in which it has invested significant sums. Therefore, the Group cannot be certain that favourable results obtained during pre-clinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the product concerned. There can be no guarantees a product will receive the necessary regulatory approvals or that the product will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the Group's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Group’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The Group also depends on third parties to develop and market some of its products which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to the Group’s activities and financial results. The Group cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of the Group’s partners could generate lower revenues than expected. Such situations could have a negative impact on the Group’s business, financial position or performance. The Group expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. The Group’s business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers. The risks and uncertainties set out are not exhaustive and the reader is advised to refer to the Group’s 2017 Registration Document available on its website (www.ipsen.com).
For further information :
Senior Vice President, Corporate Global Communications
+33 (0) 1 58 33 67 94
Vice President, Investor Relations
+44 (0) 1753 627721
Investor Relations Manager
+33 (0)1 58 33 51 04
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
The Results Are In! BOC Group Named a Leader in the Enterprise Architecture Management Suites, Q1 2019 report by Independent Research Firm25.3.2019 13:32:00 CET | Pressemelding
BOC Group, the leading global provider of Enterprise Management Solutions, announced today that it has been recognized as a “Leader” in The Forrester Wave™: Enterprise Architecture Management Suites, Q1 2019 report. Evaluated against 35 rigorous criteria, BOC Group’s EA suite ADOIT received the highest possible scores in 16 of them, including customer satisfaction, innovation agenda criteria and many others! Christoph Moser, ADOIT product manager, comments on this accomplishment by saying: “We see this achievement as an affirmation of our unwavering position as a front-runner in the EA industry and a direct reflection of the strength, depth and breadth we have incorporated across all aspects of our comprehensive, user-centric EA offering and portfolio in the last years.” Moser continues: “For us, this recognition is hard-earned and well deserved. But more importantly, we believe it further proves our strategy, relentless commitment to our customers, and continued mission to enable orga
ResMed Launches Next-generation ReSupply Solution25.3.2019 13:00:00 CET | Pressemelding
ResMed (NYSE: RMD) (ASX: RMD) today launched its automated ResMed ReSupply solution for all U.S. home medical equipment (HME) providers to increase sleep apnea patients’ long-term therapy adherence and improve patient satisfaction. Patients enrolled in an automated resupply program are 50 percent less likely to stop PAP (positive airway pressure) therapy within the first year, according to a 2018 study. ResMed’s program goes one step further, automating enrollment as patients meet compliance requirements and letting patients choose their preferred contact method – text, email or live call. Patients can also order supplies through a web- or mobile-based patient portal. HMEs are able to manage all their patients’ resupply needs from a single comprehensive dashboard so they can quickly identify, prioritize and assign tasks. “The new resupply platform is simple and easy to use – everything you need is at your fingertips,” said Kera Tennyson, a PAP location manager at Advanced Medical Solut
Sigma Systems Named Finalist for 4 Industry Awards25.3.2019 12:00:00 CET | Pressemelding
Sigma Systems, the global leader in catalog-driven software, today announced that it has been named as a finalist for two TM Forum Excellence Awards and as a semi-finalist for two Pipeline Innovation Awards. The TM Forum’s Excellence Awards highlight companies and individuals that demonstrate commitment to the evolution of the industry through digital transformation and the adoption of best practices and standards that TM Forum delivers through its Collaboration Community. Sigma is a finalist in the Service Innovator of the year and Catherine Michel is a finalist for the CTO of the Year – an award that she won in 2018. Nik Willetts, CEO, TM Forum said “Congratulations to the finalists of the TM Forum Excellence Awards 2019. As ever, the quality of the competition this year was incredibly high. With 5G fast approaching and pressure to digitally transform intensifying, it’s great to see these organizations pave the way for change and transformation. We’re excited and proud to work alongs
Newmont Announces Conditional Special Dividend25.3.2019 11:55:00 CET | Pressemelding
Newmont Mining Corporation (NYSE: NEM) (Newmont or the Company) today announced that its Board of Directors declared a one-time special dividend of $0.88 per share of common stock, conditional upon approval of the Goldcorp Inc. (NYSE: GG) (TSX: G) (Goldcorp) transaction. The dividend will be paid to Newmont shareholders of record as of April 17, 2019 (the record date), which is prior to closing of the proposed Newmont Goldcorp combination. The special dividend is conditional upon the approval by both Newmont’s and Goldcorp’s shareholders of the resolutions to be considered at their shareholder meetings on April 11 and April 4, 2019, respectively, in connection with the proposed transaction. The special dividend will be paid, subject to satisfaction of the conditions, on May 1, 2019. Closing of the Newmont Goldcorp transaction is expected shortly after the two shareholder special meetings if shareholders of both companies approve the resolutions. The special dividend delivers value to e
Tradeweb Markets Commences Roadshow for Initial Public Offering25.3.2019 11:30:00 CET | Pressemelding
Tradeweb Markets, a leading, global operator of electronic marketplaces for rates, credit, equities and money markets, today announced that it has commenced the roadshow for the initial public offering of its Class A common stock. Tradeweb Markets is offering 27,268,767 shares of its Class A common stock at an initial public offering price between $24.00 and $26.00 per share. Tradeweb Markets expects to grant the underwriters a 30-day option to purchase up to an additional 4,090,315 shares of Class A common stock at the initial public offering price, less the underwriting discounts and commissions. The shares are expected to trade on the NASDAQ Global Select Market under the ticker symbol "TW." Tradeweb intends to use the net proceeds from the offering to purchase equity interests from certain existing bank stockholders. Refinitiv will continue to own a controlling interest in Tradeweb following the offering. J.P. Morgan, Citigroup, Goldman Sachs & Co. LLC and Morgan Stanley are acting
GeoSpock and X-Locations Collaborate to Deliver Next Generation Location Data Analysis in Japan25.3.2019 11:00:00 CET | Pressemelding
GeoSpock® – the extreme-scale spatial big data integration company that provides analytics, builds insight, and enables predictions across space and time – today announced a new partnership with X-Locations – the Japan-based location AI platform company. The companies will be collaborating on a series of projects in Japan to raise awareness of the importance of location intelligence, as well as to demonstrate how and why we should be leveraging this data. The partnership will see X-Locations integrate GeoSpock’s unique spatial big data platform – which offers extreme geospatial scale and the hyper-efficient retrieval of data – into their products to improve speed of query, increase scale capacity, and reduce cost. Through the utilisation of artificial intelligence (AI) and machine learning, X-Locations accelerates the analysis and visualisation of big spatial data, enabling clients to make smarter decisions across multiple industries, including retail, real estate, manufacturing, and f